Login to Your Account

Clinic Roundup

Tuesday, November 12, 2013

• Galena Biopharma Inc., of Portland, Ore., presented a poster at the Society for Immunotherapy of Cancer Conference in National Harbor, Md., detailing results of the Phase I portion of its trial for the folate-binding protein vaccine, a cancer immunotherapy product in development for patients with HLA A2-positive cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription